Piper Sandler Reiterates Overweight Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “overweight” rating reissued by investment analysts at Piper Sandler in a research report issued on Thursday,Benzinga reports. They currently have a $163.00 price target on the specialty pharmaceutical company’s stock. Piper Sandler’s target price would suggest a potential upside of 32.48% from the company’s previous close.

JAZZ has been the topic of several other research reports. Robert W. Baird raised their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a research report on Monday, November 18th. TD Cowen cut their price objective on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Morgan Stanley upgraded shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $140.00 to $175.00 in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $140.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $177.00.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ opened at $123.04 on Thursday. The firm has a market capitalization of $7.44 billion, a PE ratio of 17.33, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The business’s fifty day moving average price is $117.39 and its 200 day moving average price is $112.11. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $134.17.

Insiders Place Their Bets

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the transaction, the chief executive officer now directly owns 427,025 shares in the company, valued at $51,742,619.25. The trade was a 0.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,753 shares of company stock valued at $816,289. 4.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in JAZZ. Itau Unibanco Holding S.A. acquired a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $29,000. EverSource Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 97 shares in the last quarter. Gladius Capital Management LP acquired a new stake in Jazz Pharmaceuticals in the second quarter valued at $33,000. GAMMA Investing LLC grew its stake in shares of Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 121 shares during the period. Finally, Venturi Wealth Management LLC grew its stake in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 704 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.